EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies

Darleen S Tu, Aaron K Olson iD, Kimberly S Waggie, Nicolas M Garcia, Virginia J Hoglund iD, Stephanie I Walter, Jenna R Rosinski iD, Harini Sadeeshkumar, Radhika Patel, Erolcan Sayar iD, Michael C Haffner, Lisa Maves und 4 weitere

Pediatric Blood & Cancer · 2026

DOI: 10.1002/pbc.32169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Darleen S Tu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Aclarubicin, Neoplasms. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sam Day Foundation, NCI NIH HHS, Sunbeam Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anthracyclines are among the most effective chemotherapeutic agents used to treat pediatric malignancies. However, their clinical use is limited by dose‐dependent toxicities, particularly cardiotoxicity and secondary malignancies. Aclarubicin (Acla) is an anthracycline derivative that induces chromatin damage while sparing DNA damage, offering potential therapeutic benefit with reduced long‐term toxicity.

Methods

We evaluated the anti‐tumor efficacy and safety profile of Acla in multiple in vitro pediatric cancer models and in vivo mouse models designed to mimic anthracycline re‐treatment following prior doxorubicin (Doxo) exposure. Tumor growth, genotoxic stress, survival, and organ toxicity were assessed.

Results

Acla demonstrated robust anti‐tumor activity comparable to Doxo across diverse pediatric in vitro models. Unlike Doxo, Acla treatment did not induce significant genotoxic stress. In vivo, mice receiving Acla after Doxo exposure showed no evidence of cumulative cardiotoxicity or end‐organ damage. In contrast, a second course of Doxo led to significant toxic mortality but was surprisingly not attributable to classic cardiac injury.

Conclusion

Our study highlights Acla as a promising anthracycline derivative for pediatric cancers, with potent anti‐tumor efficacy and a superior safety profile, even following prior anthracycline exposure. These results support continued investigation of chromatin‐damaging anthracyclines that can kill pediatric cancer cells without inducing genotoxic stress. In addition, our studies underscore the need to refine preclinical models to better understand both acute and chronic anthracycline toxicities in pediatric and adolescent populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AclarubicinNeoplasmsAnimalsMiceHumansChildFemaleXenograft Model Antitumor AssaysDNA DamageDoxorubicin

Stichwörter der Autor:innen

anthracyclinescardiotoxicityepigeneticspreclinical models

Substanzen

AclarubicinDoxorubicin

Autor:innen und Institutionen

  • Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Department of Pediatrics, University of Washington, Seattle, Washington, USA.
  • Department of Comparative Medicine, University of Washington, Seattle, Washington, USA.
  • Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Center for Developmental Biology and Regenerative Medicine, Seattle Children's Research Institute, Seattle, Washington, USA.

ORCID-Profile: Aaron K Olson, Virginia J Hoglund, Jenna R Rosinski, Erolcan Sayar, Shireen S Ganapathi

Förderung

  • Sam Day Foundation
  • NCI NIH HHS
  • Sunbeam Foundation
  • Andy Hill CARE Fund
  • Burroughs Wellcome Fund
  • CURE Childhood Cancer
  • National Cancer Institute

Zitieren

APA

Tu, D. S., Olson, A. K., Waggie, K. S., Garcia, N. M., Hoglund, V. J., Walter, S. I., Rosinski, J. R., Sadeeshkumar, H., Patel, R., Sayar, E., Haffner, M. C., Maves, L., Neefjes, J., Sarthy, J. F., Lawlor, E. R., & Ganapathi, S. S. (2026). Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32169

Vancouver

Tu DS, Olson AK, Waggie KS, Garcia NM, Hoglund VJ, Walter SI, et al. Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies. Pediatric Blood & Cancer. 2026. doi:10.1002/pbc.32169

BibTeX
@article{Tu2026,
  author = {Tu, Darleen S and Olson, Aaron K and Waggie, Kimberly S and Garcia, Nicolas M and Hoglund, Virginia J and Walter, Stephanie I and Rosinski, Jenna R and Sadeeshkumar, Harini and Patel, Radhika and Sayar, Erolcan and Haffner, Michael C and Maves, Lisa and Neefjes, Jacques and Sarthy, Jay F and Lawlor, Elizabeth R and Ganapathi, Shireen S},
  title = {Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/pbc.32169}
}
Kostenlos starten →